BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodriguez-Cuenca S, Carobbio S, Barceló-Coblijn G, Prieur X, Relat J, Amat R, Campbell M, Dias AR, Bahri M, Gray SL, Vidal-Puig A. P465L-PPARγ mutation confers partial resistance to the hypolipidaemic action of fibrates. Diabetes Obes Metab 2018;20:2339-50. [PMID: 29790245 DOI: 10.1111/dom.13370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Hong F, Xu P, Zhai Y. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. Int J Mol Sci 2018;19:E2189. [PMID: 30060458 DOI: 10.3390/ijms19082189] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 14.8] [Reference Citation Analysis]
2 Rochford JJ. When Adipose Tissue Lets You Down: Understanding the Functions of Genes Disrupted in Lipodystrophy. Diabetes 2022;71:589-98. [PMID: 35316838 DOI: 10.2337/dbi21-0006] [Reference Citation Analysis]
3 Rodriguez-Cuenca S, Carobbio S, Barceló-Coblijn G, Prieur X, Relat J, Amat R, Campbell M, Dias AR, Bahri M, Gray SL, Vidal-Puig A. P465L-PPARγ mutation confers partial resistance to the hypolipidaemic action of fibrates. Diabetes Obes Metab 2018;20:2339-50. [PMID: 29790245 DOI: 10.1111/dom.13370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Rodriguez-Cuenca S, Lelliot CJ, Campbell M, Peddinti G, Martinez-Uña M, Ingvorsen C, Dias AR, Relat J, Mora S, Hyötyläinen T, Zorzano A, Orešič M, Bjursell M, Bohlooly-Y M, Lindén D, Vidal-Puig A. Allostatic hypermetabolic response in PGC1α/β heterozygote mouse despite mitochondrial defects. FASEB J 2021;35:e21752. [PMID: 34369602 DOI: 10.1096/fj.202100262RR] [Reference Citation Analysis]